Guide Peri-Op Management of Direct Oral Anticoagulants

You’ll be asked how to manage direct oral anticoagulants (DOACs) around procedures or surgery.

Collaborate with colleagues...consider these rules of thumb...and ensure that the peri-op plan is clearly documented for the team.

Holding. Stop and restart based on procedure and patient risks.

Generally hold DOACs 1 day before procedures with low bleeding risk, such as colonoscopy or upper endoscopy...since these may involve biopsy or polyp removal.

Typically hold DOACs for 2 days before procedures with high bleeding risk, such as abdominal or vascular surgery.

Don’t be surprised if some anesthesiologists use a more conservative approach with regional anesthesia...such as holding for 3 days or more.

And consider other factors...such as kidney function.

For example, if CrCl is below 50 mL/min, hold dabigatran (Pradaxa) for 2 days before low-bleeding-risk procedures...or 4 days before high-bleeding-risk procedures. Dabigatran relies on renal clearance more than other DOACs.

Usually restart DOACs at least 1 day after low-bleeding-risk procedures...or 2 to 3 days after high-bleeding-risk surgeries.

Keep in mind, it’s often okay to continue DOACs for procedures with minimal bleeding risk...such as tooth extraction or skin biopsy.

In these cases, delay DOACs on the day of surgery until 4 to 6 hours post-op. This may mean skipping the morning dose of twice-daily DOACs.

Bridging. Don’t routinely bridge DOACs. Risk of bleeding seems to outweigh any benefit...plus DOACs have a rapid onset when resumed.

Reversing. Limit peri-op DOAC reversal to life-threatening emergencies.

Andexanet alfa (Andexxa) is a specific reversal agent for factor Xa inhibitors, such as apixaban (Eliquis) or rivaroxaban (Xarelto)...but don’t be surprised if it’s non-formulary.

Data are limited...and andexanet alfa costs up to $23,000/dose.

To reverse factor Xa inhibitors, expect many hospitals to use 4-factor prothrombin complex concentrate (KcentraBalfaxar). It costs about $6,000 for a fixed dose of 2,000 units.

If dabigatran reversal is required, anticipate that idarucizumab (Praxbind) will be used. It corrects coagulation labs prior to emergent surgery...but outcomes data are limited. It costs $4,000/dose.

Review our resource, Peri-Op Management of Chronic Meds, for guidance about managing warfarin, and more.

Key References

  • Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-1676.
  • Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022 Nov;162(5):e207-e243.
  • Levy JH, Mamoun N. Direct oral anticoagulants and their antagonists in perioperative practice. Curr Opin Anaesthesiol. 2023 Aug 1;36(4):394-398.
  • Medication pricing by Elsevier, accessed May 2024.
Prescriber Insights. June 2024, No. 400603



Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote